Fresenius Kabi USA announced its launch of Acetylcysteine Solution 20% in 4mL vials for inhalation or oral administration.
Acetylcysteine Solution is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: chronic bronchopulmonary disease, acute bronchopulmonary disease, pulmonary complications of cystic fibrosis, tracheostomy care, pulmonary complications associated with surgery, use during anesthesia, post-traumatic chest conditions, atelectasis due to mucous obstruction, diagnostic bronchial studies. Inhalation therapy reduces the viscosity of mucus, thinning mucus secretions. When administered orally, it is indicated as an antidote to prevent or lessen hepatic injury following acetaminophen overdose.
RELATED: Respiratory Disorders Resource Center
Acetylcysteine Solution has been on the FDA and the American Society of Health-System Pharmacists (ASHP) drug shortage lists since 2011. In 2012, Fresenius Kabi introduced the 20% concentration in 10mL vials, and in 2013, the company launched 30mL vials and injection versions of the product.
For more information call (847) 550-7121 or visit Fresenius-Kabi.us.